¶ National Advisory Committee on Immunization
.png)
The National Advisory Committee on Immunization (NACI) is a Canadian advisory body operating within the Public Health Agency of Canada (PHAC).[1] It is tasked with “providing guidance on the use of vaccines currently or newly approved for use in Canada to the Government of Canada.”[2]
¶ History
NACI was formed in 1964.[2:1]
¶ COVID-19
On April 23, 2021, NACI recommended the AstraZeneca-Oxford COVID-19 vaccine be offered to “all Canadians over the age of 30, but only when the benefits outweigh the risks of rare, serious post-vaccine blood clots.”[3]
On June 29, 2022, NACI issued guidance recommending “booster doses” of COVID-19 vaccines for all “Canadians at increased risk of serious illness from COVID-19,” regardless of how many doses they had previously received.[4]
On March 3, 2023, NACI called for “high-risk individuals” to receive another booster dose in the spring.[5][6]
On July 11, 2023, NACI once again strongly recommended that all individuals over the age of 5 receive a "primary series" of COVID-19 vaccines, with a less emphatic recommendation for those aged 6 months to five years. They also recommended an additional dose of "the new formulation of COVID-19 vaccine for individuals in the authorized age group if it has been at least 6 months from the previous COVID-19 vaccine dose or known SARS-CoV-2 infection."[7][8]
¶ Personnel
| Name | Position | Notes |
|---|---|---|
| Shelley Deeks | Chair[9] | Nova Scotia Department of Health and Wellness |
| Robyn Harrison | Vice-chair | Grey Nuns Community Hospital, University of Alberta Hospital |
| Melissa Andrew | Member | Dalhousie University |
| Julie Bettinger | Member | University of British Columbia |
| Nicholas Brousseau | Member | Laval University |
| Hélène Decaluwe | Member | Research Centre of the Sainte-Justine University Hospital |
| Philippe De Wals | Member | Laval University Department of Social and Preventive Medicine |
| Eve Dubé | Member | Institut national de santé publique du Québec |
| Vinita Dubey | Member | Toronto Public Health |
| Kyla Hildebrand | Member | University of British Columbia |
| Kristin Klein | Member | Alberta Health Services |
| Miranda O'Driscoll | Member | Newfoundland and Labrador Department of Health and Community Services |
| Jesse Papenburg | Member | McGill University Health Centre (MUHC) |
| Anne Pham-Huy | Member | Children's Hospital of Eastern Ontario (CHEO) |
| Beate Sander | Member | Toronto General Hospital |
| Sarah Wilson | Member | Public Health Ontario |
| Natalie Dayneka | Member (former)[10] | Children's Hospital of Eastern Ontario (CHEO) |
| Soren Gantt | Member (former) | University of Montreal |
| Coleman Rotstein | Member (former) | University of Toronto |
| Althea House | Member (former) | Public Health Agency of Canada |
| Matthew Tunis | Executive secretary | - |
| Jeannette Comeau | Liaison representative | Association of Medical Microbiology and Infectious Disease Canada (AMMI) |
| Sarah Buchan | Liaison representative | Canadian Association for Immunization Research and Evaluation (CAIRE) |
| Monika Naus | Liaison representative | Canadian Immunization Committee (CIC) |
| Lea Bill | Liaison representative | Canadian Indigenous Nurses Association |
| Lucie Marisa Bucci | Liaison representative | Canadian Public Health Association (CPHA) |
| Amanda Ung | Liaison representative | Canadian Pharmacists Association |
| Dorothy Moore | Liaison representative | Canadian Paediatric Society |
| Martin Lavoie | Liaison representative | Council of Chief Medical Officers of Health |
| Jessica MacNeil | Liaison representative | Centers for Disease Control and Prevention (CDC) |
| Melanie Osmack | Liaison representative | Indigenous Physicians Association of Canada |
| Eliana Castillo | Liaison representative | Society of Obstetrics and Gyneacologists |
| Vacant | Liaison representative | Canadian Nurses Association |
| Jen Potter | Liaison representative | College of Family Physicians of Canada |
| Julie Emili | Liaison representative (former) | College of Family Physicians of Canada |
| Co Pham | Ex-officio | Biologics and Genetic Therapies Directorate |
| Robert Pless | Ex-officio (former) | Biologics and Genetic Therapies Directorate |
| Vincent Beswick-Escanlar | Ex-officio | Directorate of Force Health Protection |
| Ming Su | Ex-officio | Public Health Agency of Canada |
| Erin Henry | Ex-officio | Centre for Immunization Readiness (CIR) |
| Patrick Fandja | Ex-officio | Marketed Health Products Directorate |
| Deborah Danoff | Ex-officio (former) | Marketed Health Products Directorate |
| Michael Routledge | Ex-officio | National Microbiology Laboratory |
| Susanna Ogunnaike-Cooke | Ex-officio | Public Health Agency of Canada |
| Tom Wong | Ex-officio | First Nations and Inuit Health Branch |
| Mireille Lacroix | Ex-officio | Public Health Ethics Consultative Group (PHECG) |
¶ Publications
NACI's official statements about COVID-19 vaccines are as follows:[11]
- December 12, 2020: Recommendations on the use of COVID-19 vaccine(s)
- December 23, 2020: Recommendations on the use of COVID-19 vaccines
- January 12, 2021: Recommendations on the use of COVID-19 vaccines
- March 1, 2021: Recommendations on the use of COVID-19 vaccines
- March 3, 2021: NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada
- March 16, 2021: Recommendations on the use of COVID-19 vaccines
- March 29, 2021: NACI rapid response: Recommended use of AstraZeneca COVID-19 vaccine in younger adults
- April 7, 2021: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply
- April 23, 2021: Recommendations on the use of COVID-19 vaccines
- May 3, 2021: Recommendations on the use of COVID-19 vaccines
- May 18, 2021: Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine in adolescents 12 to 18 years of age
- May 28, 2021: Recommendations on the use of COVID-19 vaccines
- June 1, 2021: Interchangeability of authorized COVID-19 vaccines
- June 17, 2021: Recommendations on the use of COVID-19 vaccines
- July 2, 2021: Recommendations on the use of COVID-19 vaccines
- July 22, 2021: Recommendations on the use of COVID-19 vaccines
- August 27, 2021: Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age
- September 10, 2021: National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series
- September 28, 2021: Recommendations on the use of COVID-19 vaccines
- September 28, 2021: NACI rapid response: Booster dose in long-term care residents and seniors living in other congregate settings
- October 22, 2021: Recommendations on the use of COVID-19 vaccines
- December 12, 2020-October 22, 2021: Table of updates: Recommendations on the use of COVID-19 vaccines
- October 29, 2021: Interim guidance on booster COVID-19 vaccine doses in Canada
- November 19, 2021: Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age
- December 3, 2021: NACI rapid response: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines
- December 3, 2021: NACI updated guidance on booster COVID-19 vaccine doses in Canada
- January 25, 2022: NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age
- January 28, 2022: NACI rapid response: Guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age
- February 4, 2022: NACI rapid response: Updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2
- February 17, 2022: Recommendations on the use of Novavax Nuvaxovid COVID-19 vaccine
- March 11, 2022: Recommendations on the use of Medicago COVID-19 vaccine (Covifenz)
- March 17, 2022: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 to 11 years of age
- April 5, 2022: Initial guidance on a second booster dose of COVID-19 vaccines in Canada
- April 12, 2022: Updated guidance on a first booster dose of COVID-19 vaccines in Canada
- June 29, 2022: Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada
- July 14, 2022: Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age
- August 19, 2022: Recommendations on the use of a first booster dose of Pfizer-BioNTech Comirnaty COVID-19 vaccine in children 5 to 11 years of age
- September 1, 2022: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines
- September 9, 2022: Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding
- October 7, 2022: Updated guidance on COVID-19 vaccine booster doses in Canada
- October 21, 2022: Recommendations on the use of Pfizer-BioNTech Comirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age
- November 3, 2022: Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022: Recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults
- December 9, 2022: Updated recommendations on the use of COVID-19 vaccine booster doses in children 5 to 11 years of age and concurrent vaccine administration
- January 20, 2023: Guidance on COVID-19 vaccine booster doses: Initial considerations for 2023
- March 3, 2023: Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19
- June 9, 2023: Interim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series
- July 11, 2023: Guidance on the use of COVID-19 vaccines in the fall of 2023
- September 12, 2023: Addendum to the guidance on the use of COVID-19 vaccines in the fall of 2023
- October 27, 2023: Updated guidance on the use of COVID-19 vaccines in individuals who have not previously been vaccinated against COVID-19
- January 12, 2024: Guidance on an additional dose of COVID-19 vaccines in the spring for individuals at high risk of severe illness due to COVID-19
¶ External links
Public Health Agency of Canada. (2022, September 16). National Advisory Committee on Immunization (NACI): Terms of reference. Government of Canada. https://web.archive.org/web/20230406185629/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/terms-references.html ↩︎
Public Health Agency of Canada. (2022, April 22). National Advisory Committee on Immunization (NACI): Membership and representation. Government of Canada. http://archive.today/2022.04.24-045738/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html ↩︎ ↩︎
Pelley, L. (2021, April 23). Canadians over 30 should be offered AstraZeneca-Oxford COVID-19 vaccine, advisory body recommends. CBC News. http://archive.today/2021.04.24-073245/https://www.cbc.ca/news/health/astrazeneca-covid-19-vaccine-over-30-naci-1.6000052 ↩︎
Boynton, S. (2022, June 19). COVID-19 boosters recommended this fall ahead of future pandemic wave: NACI. Global News. http://archive.today/2023.04.19-201142/https://globalnews.ca/news/8957899/naci-covid-19-boosters-fall-canada/ ↩︎
National Advisory Committee on Immunization. (2023, March 3). Guidance on an additional COVID-19 booster dose in the spring of 2023 for individuals at high risk of severe illness due to COVID-19. Public Health Agency of Canada. https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/vaccines-immunization/national-advisory-committee-immunization-guidance-additional-covid-19-booster-dose-spring-2023-individuals-high-risk-severe-illness-due-covid-19/statement.pdf ↩︎
Pelley, L. (2023, March 3). COVID-19 booster shots recommended for high-risk Canadians starting this spring. CBC News. https://web.archive.org/web/20230419211957/https://www.cbc.ca/news/health/covid-booster-recommendations-1.6767057 ↩︎
National Advisory Committee on Immunization. (2023, July 13). Guidance on the use of COVID-19 vaccines in the fall: NACI, July 11, 2023. Public Health Agency of Canada. http://archive.today/2023.07.20-193232/https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/national-advisory-committee-immunization-guidance-use-covid-19-vaccines-fall-2023.html ↩︎
Ireland, N. (2023, July 11). Get another COVID-19 booster in the fall, Canada’s immunization panel recommends. CTV News. http://archive.today/2023.07.13-123458/https://www.ctvnews.ca/health/coronavirus/get-another-covid-19-booster-in-the-fall-canada-s-immunization-panel-recommends-1.6475413 ↩︎
Public Health Agency of Canada. (2022, April 22). National Advisory Committee on Immunization (NACI): Membership and representation. Government of Canada. http://archive.today/2022.04.24-045738/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html ↩︎
National Advisory Committee on Immunization (NACI): Membership and representation. (2020, December 18). Wayback Machine; Government of Canada. https://web.archive.org/web/20201218222110/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html ↩︎
Public Health Agency of Canada. (2024, January 12). National Advisory Committee on Immunization (NACI): Statements and publications. Government of Canada. https://web.archive.org/web/20240224194925/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci.html ↩︎